Focus on AVLAYAH launch trajectory: Q3 guidance of $10-12M implies rapid quarter-over-quarter growth, which could drive upside if sustained. However, the DNL151 failure and DNL593 delay remove near-term pipeline catalysts. Monitor the Q3 revenue print and any updates on the DNL126 BLA submission timeline for 2027.
Drug in focus
DNLI drug pipeline →tividenofusp alfa-eknm
● Neutral Named in this 8-K- Impact
- Phase
- Approved (accelerated approval)
- Time to market
- Already approved and commercially launched in the U.S. (March 2026). Global regulatory submissions are expected to follow the ongoing Phase 2/3 COMPASS confirmatory trial.
- Next catalyst
- None dated
What to watchThe next near-term catalyst is Denali's Q3 2026 earnings report on November 4, 2026, where management's Q3 Avlayah revenue (guided $10-12M, up from $3.6M in Q2) will be the key commercial proof point. The longer-term binary is the confirmatory Phase 2/3 COMPASS trial readout, which will determine whether the accelerated approval converts to full approval, though no specific readout date has been announced.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 7 $24.83entry
- T+1 · 3mo ago +0.68%α +0.71% · $25.00
- T+5 · 3mo ago −1.73%α −2.13% · $24.40
- T+20 · 2mo ago −10.27%α −9.87% · $22.28
- T+60 · 15d ago −24.53%α −22.39% · $18.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Denali Therapeutics reported Q2 2026 results with AVLAYAH generating $3.6M in its first full commercial quarter, beating consensus revenue estimates of $2.2M. EPS of -$0.68 missed consensus of -$0.47 due to commercial build costs and lower interest income. Q3 AVLAYAH revenue guidance of $10-12M signals accelerating uptake, partially offsetting the negative pipeline news of the DNL151 (LRRK2) Phase 2b failure and the DNL593 (FTD-GRN) data delay to 2027.
Key Financial Metrics
Key Facts
- AVLAYAH net product revenue of $3.6M in Q2 2026, first full quarter of launch
- Q3 2026 AVLAYAH revenue guidance of $10.0M to $12.0M
- EPS of -$0.68 vs consensus -$0.47 (miss of 44.7%)
- Net loss of $127.6M vs $124.1M in Q2 2025
- Cash, equivalents and marketable securities ~$940M at June 30; pro forma >$1.1B after $195M PRV sale in July
- DNL151 (LRRK2) Phase 2b LUMA study failed; development discontinued in idiopathic Parkinson's
- DNL593 (FTD-GRN) Phase 1/2 data now expected in 2027 (previously end of 2026)
- FDA granted Orphan Drug Designation to DNL593 for FTD-GRN in August 2026
Financial Impact
Revenue beat of $1.4M (63.6%) vs consensus; EPS miss of $0.21 (44.7%) vs consensus; cash strengthened by $195M PRV sale
Risk Factors
- AVLAYAH launch may not sustain momentum if payer coverage or patient starts slow
- DNL151 failure removes a major pipeline asset; DNL593 delay pushes key data out
- Competition from other Hunter syndrome therapies (e.g., Takeda's Elaprase) and emerging BBB-penetrating drugs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001714899-26-000096 |
| Document: dnli-20260806.htm | 0001714899-26-000096 |
| Document: 0001714899-26-000096-index-headers.html | 0001714899-26-000096 |
| Document: 0001714899-26-000096-index.html | 0001714899-26-000096 |
| Document: 0001714899-26-000096.txt | 0001714899-26-000096 |
| 8-K Data (Synthetic) | 0001714899-26-000096 |
Track record
17 reports on DNLI
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
- Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
- Aug 6, 202614w ago 8-K Mixed 6/10 Viewing Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
- Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
- Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers